Logo image of HBP.CA

HELIX BIOPHARMA CORP (HBP.CA) Stock Fundamental Analysis

Canada - Toronto Stock Exchange - TSX:HBP - CA4229102088 - Common Stock

2.34 CAD
+0.01 (+0.43%)
Last: 12/5/2025, 7:00:00 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to HBP. HBP was compared to 23 industry peers in the Biotechnology industry. HBP may be in some trouble as it scores bad on both profitability and health. HBP is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

HBP had negative earnings in the past year.
In the past year HBP has reported a negative cash flow from operations.
HBP had negative earnings in each of the past 5 years.
In the past 5 years HBP always reported negative operating cash flow.
HBP.CA Yearly Net Income VS EBIT VS OCF VS FCFHBP.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -2M -4M -6M -8M -10M

1.2 Ratios

With a decent Return On Assets value of -27.68%, HBP is doing good in the industry, outperforming 73.91% of the companies in the same industry.
With a decent Return On Equity value of -33.40%, HBP is doing good in the industry, outperforming 73.91% of the companies in the same industry.
Industry RankSector Rank
ROA -27.68%
ROE -33.4%
ROIC N/A
ROA(3y)-420.37%
ROA(5y)-326.96%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HBP.CA Yearly ROA, ROE, ROICHBP.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20K 40K 60K

1.3 Margins

HBP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HBP.CA Yearly Profit, Operating, Gross MarginsHBP.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

3

2. Health

2.1 Basic Checks

Compared to 1 year ago, HBP has more shares outstanding
The number of shares outstanding for HBP has been reduced compared to 5 years ago.
Compared to 1 year ago, HBP has a worse debt to assets ratio.
HBP.CA Yearly Shares OutstandingHBP.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
HBP.CA Yearly Total Debt VS Total AssetsHBP.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M

2.2 Solvency

An Altman-Z score of 16.29 indicates that HBP is not in any danger for bankruptcy at the moment.
HBP has a better Altman-Z score (16.29) than 95.65% of its industry peers.
HBP has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of HBP (0.02) is better than 78.26% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 16.29
ROIC/WACCN/A
WACCN/A
HBP.CA Yearly LT Debt VS Equity VS FCFHBP.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M -5M 10M -10M 15M

2.3 Liquidity

A Current Ratio of 0.13 indicates that HBP may have some problems paying its short term obligations.
With a Current ratio value of 0.13, HBP is not doing good in the industry: 65.22% of the companies in the same industry are doing better.
HBP has a Quick Ratio of 0.13. This is a bad value and indicates that HBP is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.13, HBP is not doing good in the industry: 60.87% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.13
Quick Ratio 0.13
HBP.CA Yearly Current Assets VS Current LiabilitesHBP.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M

More info and screens

0

3. Growth

3.1 Past

HBP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 50.15%, which is quite impressive.
EPS 1Y (TTM)50.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.76%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
HBP.CA Yearly EPS VS EstimatesHBP.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 -0.1 -0.2 -0.3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for HBP. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HBP.CA Price Earnings VS Forward Price EarningsHBP.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HBP.CA Per share dataHBP.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 0.2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for HBP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HELIX BIOPHARMA CORP

TSX:HBP (12/5/2025, 7:00:00 PM)

2.34

+0.01 (+0.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-22 2025-10-22
Earnings (Next)12-15 2025-12-15
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners7.71%
Ins Owner ChangeN/A
Market Cap178.73M
Revenue(TTM)N/A
Net Income(TTM)-5.21M
Analysts80
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 11.47
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.1
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)-0.05
OCFYN/A
SpS0
BVpS0.2
TBVpS-0.04
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -27.68%
ROE -33.4%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-420.37%
ROA(5y)-326.96%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 20%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.13
Quick Ratio 0.13
Altman-Z 16.29
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)65.64%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.76%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y41.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y26.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y26.6%
OCF growth 3YN/A
OCF growth 5YN/A

HELIX BIOPHARMA CORP / HBP.CA FAQ

Can you provide the ChartMill fundamental rating for HELIX BIOPHARMA CORP?

ChartMill assigns a fundamental rating of 1 / 10 to HBP.CA.


Can you provide the valuation status for HELIX BIOPHARMA CORP?

ChartMill assigns a valuation rating of 0 / 10 to HELIX BIOPHARMA CORP (HBP.CA). This can be considered as Overvalued.


What is the profitability of HBP stock?

HELIX BIOPHARMA CORP (HBP.CA) has a profitability rating of 1 / 10.